P450-Mediated O-Demethylated Metabolite Is Responsible for Rat Hepatobiliary Toxicity of Pyridyltriazine-Containing PI3K Inhibitors

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

(2015)   Oncotarget

New Molecular Targets in the Treatment of NSCLC

(2013) Clorinda Schettino et al.   CURRENT PHARMACEUTICAL DESIGN

PKB/Akt-Dependent Regulation of Cell Motility

(2013) G. Xue et al.   JNCI-Journal of the National Cancer Institute

Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases

(2012) Adrian L. Smith et al.   JOURNAL OF MEDICINAL CHEMISTRY

Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511

(2012) Mark H. Norman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors

(2011) Noel D. D’Angelo et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability

(2011) Markian M. Stec et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure–Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives

(2011) Nobuko Nishimura et al.   JOURNAL OF MEDICINAL CHEMISTRY

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

(2010) P. Workman et al.   CANCER RESEARCH

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

(2009) N. T. Ihle et al.   MOLECULAR CANCER THERAPEUTICS